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ABSTRACT
Genomic surveillance of SARS-CoV-2 was rapidly implemented in Portugal by the National Institute of Health in
collaboration with a nationwide consortium of >50 hospitals/laboratories. Here, we track the geotemporal spread of a
SARS-CoV-2 variant with a mutation (D839Y) in a potential host-interacting region involving the Spike fusion peptide,
which is a target motif of anti-viral drugs that plays a key role in SARS-CoV-2 infectivity. The Spike Y839 variant was
most likely imported from Italy in mid-late February and massively disseminated in Portugal during the early
epidemic, becoming prevalent in the Northern and Central regions of Portugal where it represented 22% and 59% of
the sampled genomes, respectively, by 30 April. Based on our high sequencing sampling during the early epidemics
[15.5% (1275/8251) and 6.0% (1500/24987) of all confirmed cases until the end of March and April, respectively], we
estimate that, between 14 March and 9 April (covering the epidemic exponential phase) the relative frequency of the
Spike Y839 variant increased at a rate of 12.1% (6.1%–18.2%, CI 95%) every three days, being potentially associated
with 24.8% (20.8–29.7%, CI 95%; 3177–4542 cases, CI 95%) of all COVID-19 cases in Portugal during this period. Our
data supports population/epidemiological (founder) effects contributing to the Y839 variant superspread. The
potential existence of selective advantage is also discussed, although experimental validation is required. Despite
huge differences in genome sampling worldwide, SARS-CoV-2 Spike D839Y has been detected in 13 countries in four
continents, supporting the need for close surveillance and functional assays of Spike variants.
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Introduction
The causative agent of COVID-19, the novel corona-
virus SARS-CoV-2 (Severe Acute Respiratory Syn-
drome Coronavirus 2), is a tremendous global
threat, already leading to nearly 25 million confirmed
cases and approximately 800 thousand deaths world-
wide, as of 30 August 2020 [1]. The Spike protein gov-
erns the binding of SARS-CoV-2 with its receptor
angiotensin-converting enzyme 2 (ACE2) in human
cells, the fusion between the viral and host cell mem-
branes and, thus, the virus entry [2–8]. This protein,
which decorates the virion surface, also induces neu-
tralizing antibodies and is therefore the key target
for vaccine development [2,5,9]. In this context, it is
of upmost importance to track the genetic diversity
and evolution of circulating SARS-CoV-2 at regional
and global levels, with special focus on detecting the
emergence and monitoring the spread of Spike var-
iants. Although surveillance has been expectedly
focused on genetic changes affecting the Spike recep-
tor binding domain (RBD) [2,10–12], changes in
other domains should also be closely surveyed, par-
ticularly when they are linked to variant frequency
increase at local, regional or global levels [13,14]. A
variant carrying the Spike D614G mutation stands
out as a remarkable example, as it became dominant
worldwide during the first months of the pandemic
[13,15,16] with recent studies suggesting that the
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G614 variant might be linked to an increased trans-
missibility but not pathogenicity [13]. Spike amino
acid 614 is pocketed adjacent to the fusion peptide,
which is the functional fusogenic element of the
Spike protein [2], and near the expected cleavage
site, suggesting that G614 might have induced a con-
formational change influencing the dynamics of the
spatially proximal fusion peptide, thereby resulting
in the altered infectivity [13]. Hence, other mutations
of interest outside the RBD have been highlighted
[13], particularly those falling within the Spike fusion
peptide or proximal regions [2,13], due to the critical
role of these motifs in inserting SARS-CoV-2 into the
membrane of human cells [2,17]. The fusion mechan-
ism is also pointed out as an important target for the
development of specific drugs against coronavirus,
since it is expectedly less mutable than the surface-
exposed and immunogenic RBD [2,18]. The Spike
amino acid 839, within the fusion peptide or proximal
regions (there is still no consensus on their precise
location) [2], is being highlighted due to its potential
specific host-interacting role in Spike cleavage for
SARS-CoV-2 fusion activation and/or in the induction
of host inflammatory responses [13,19,20].
Here, we evaluated the temporal and geographical
spread of a SARS-CoV-2 variant carrying the Spike
protein amino acid change D839Y that had a massive
dissemination during the early COVID-19 epidemic
in Portugal after its introduction from Italy in mid-
late February. After the globally dispersed Spike
D614G mutation, this is the first study reporting the
superspread of a Spike variant with a tremendous epi-
demiological impact at country level.
Material and methods
A detailed description of methods is available as Sup-
plementary material.
Sample characterization
Samples used in this study were collected as part of the
ongoing national SARS-CoV-2 laboratory surveillance
conducted by the National Institute of Health (INSA)
Doutor Ricardo Jorge, Portugal. SARS-CoV-2 positive
samples (either clinical specimens or RNA) were pro-
vided by a nationwide network with >50 laboratories
that was established at the beginning of the epidemic
in Portugal. Available demographic information,
date of sample collection, date of illness onset and tra-
vel history were provided by laboratories and Regional
and National Health Authorities. Geographical data
presented in this study refers to the Region (“Health
Administration region”), District or Municipality of
the patients’ residence or, when no information is
available (for a small proportion of cases), to the
location of exposure or of the hospital/laboratory
that collected/sent the sample.
SARS-CoV-2 genome sequencing and analysis
After cDNA synthesis, SARS-CoV-2 positive RNA
samples were subjected to amplicon-based whole-gen-
ome amplification with tiled, multiplexed primers
[21], following the Artic Consortium protocol
(https://artic.network/ncov-2019; https://www.
protocols.io/view/ncov-2019-sequencing-protocol-
bbmuik6w). After Illumina NexteraXT library prep-
aration, paired-end sequencing was performed either
on Illumina MiSeq or NextSeq 550, targeting ∼1M
reads per sample.
Analysis of sequence read data was conducted using
the bioinformatics pipeline implemented in INSaFLU
(https://insaflu.insa.pt/; https://github.com/
INSaFLU), which is a web-based (and also locally
installable) platform for amplicon-based next-gener-
ation sequencing data analysis [22].
Phylogenetic analysis and real-time data
sharing on SARS-CoV-2 genetic diversity and
geotemporal spread in Portugal
A total of 1516 SARS-CoV-2 genome sequences were
analyzed in this study (corresponding to INSA’s col-
lection as of 23 July 2020; Table S1) using the SARS-
CoV-2 Nextstrain pipeline [23] version from March
23, 2020 (https://github.com/nextstrain/ncov).
A website (https://insaflu.insa.pt/covid19) was
launched on March 28, 2020 for real-time data sharing
on SARS-CoV-2 genetic diversity and geotemporal
spread in Portugal, giving access to “situation reports”
of the study and providing interactive data navigation
using both Nextstrain (https://nextstrain.org/) [23]
and Microreact (https://microreact.org/) [24] tools.
To explore the frequency of Spike D839Y variant at
worldwide level, we downloaded all the amino acid
sequences (and associated metadata) of SARS-CoV-2
spike protein available at GISAID (as of 23 July
2020). The genome sequences with the D839Y
mutation detected abroad were downloaded from
GISAD (Table S2) and subjected to clade classification
and integration into “global” and Portugal phylogeny
using Nextstrain (https://nextstrain.org/ncov) and
Nextclade (https://clades.nextstrain.org/).
Statistical analysis
In order to assess the temporal variation in the pro-
portion of D839Ymutation among sequenced samples,
a binomial regression model with logarithmic link
function was applied. The model was then applied to
extrapolate the evolution of Y839 cases in the total
case population (data presented in Figure 4). To
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increase the robustness of the analysis, the studied
timeframe (from 14 March to 9 April, overlapping
the exponential phase of the epidemic in Portugal)
was adjusted to ensure 3-days bins with at least 25 gen-
ome sequences. We assumed one day as the timeframe
delay between sample collection and case notification.
The Kruskal-Walls non-parametric test was used to
assess the existence of statistically significant differ-
ences in Ct values between groups (Figure S4). Differ-
ences in Ct values for each pair of groups were
assessed using the Wilcoxon test adjusted for multiple
comparison tests.
Data availability
SARS-CoV-2 genome sequences generated in this
study were uploaded to GISAID database (https://
www.gisaid.org/). Accession numbers can be found
in Supplementary material (Table S1).
Results
Introduction and spread of the SARS-CoV-2
Spike Y839 variant in Portugal
Acting as the National Reference Laboratory for
SARS-CoV-2, INSA rapidly established the genome-
based molecular surveillance of SARS-CoV-2 in Por-
tugal. A website (https://insaflu.insa.pt/covid19) was
launched, providing updated data regarding the analy-
sis of the SARS-CoV-2 genetic diversity and geotem-
poral spread. As of July 23, 2020, INSA had analysed
1516 genome sequences (Table S1), enrolling 15.5%
(1275/8251) and 6.0% (1500/24987) of all confirmed
cases detected until the end of March and April,
respectively. According to Nextstrain clade definition
(https://clades.nextstrain.org/), the 1516 SARS-CoV2
genomes from Portugal (https://microreact.org/
project/nDGsJKFv7gQTj1q8CQwwKR/18a0a470) fol-
low, in general, the same trend observed at European
level (https://nextstrain.org/ncov/europe) [15,25].
Most viruses (89.8%) integrate the phylogenetic
branch enrolling clades 20A (40.8%), 20B (46.1%)
and 20C (2.9%), carrying, among other genetic mar-
kers, the D614G amino acid replacement in the
Spike protein [13,15,16]. Clades 19A and 19B were
found at the relative frequencies of 7.4% and 2.8%,
respectively.
Within clade 20A, a SARS-CoV-2 variant carrying
the Spike amino acid change D839Y (due to a
G24077 T SNP) was detected early (7 March 2020)
during the COVID-19 epidemic in Portugal. The
Spike Y839 variant was most likely imported from
Italy in mid-late February 2020, as first detected gen-
omes were all collected from individuals from the
Northern region of Portugal that contacted (primarily
or secondarily) with epidemiologically linked infected
individuals that had been in Milan for an international
trade fair during the third week of February 2020.
Concordantly, the first D839Y genome sequence
reported worldwide was collected in Italy (Lombardy)
on 21 February (Italy/PV-5314-N/2020; GISAID
accession number EPI_ISL_451307) (Table S2) [26],
being identical (i.e, Nextstrain clade 20A background
plus the G24077 T SNP) to the “founder” Spike
Y839 variant genome sequences detected in Portugal
(https://insaflu.insa.pt/covid19). So far, current data
and ongoing epidemiological investigations support
a single origin (Milan, Italy) and, although there was
a substantial representation of Portuguese companies
in this event, available data links the introduction of
the Y839 variant in Portugal to a single industrial
area in the North of Portugal. The Spike Y839 variant
became particularly prevalent in Portugal, representing
about 20% of all sampled genomes collected until the
end of March (255/1275) or the end of April (287/
1500) (Figure 1). Its circulation was particularly marked
inNorthern (epicenter ofCOVID-19 epidemic inPortu-
gal) and Central regions of Portugal, representing 22%
and 59% of the sampled genomes, respectively, by the
end of April 2020 (Figures 2 and 3; https://microreact.
org/project/nDGsJKFv7gQTj1q8CQwwKR/0489f840).
In the same period, four districts (with at least 50 gen-
omes sampled as of 30 April) revealed the highest
Y839 relative frequency: Braga (16.3%), Porto (25.2%),
Aveiro (68.1%) and Guarda (72.7%) (Figure S1). We
estimate that the relative frequency of Y839 increased
Figure 1. Overview of the SARS-CoV-2 genome sequencing
sampling in Portugal and cumulative relative frequency of
the circulating Spike Y839 variant, as of 30 April 2020 (n =
1500). Area plots (left y-axis) reflect the cumulative total num-
ber of SARS-CoV-2 genome sequences (gray) and Spike Y839
variant sequences (red) obtained in Portugal during the first
two months of the epidemic. Lines (right y-axis) display the
cumulative percentage of COVID-19 confirmed cases for
which SARS-CoV-2 genome data was generated (“sequencing
sampling” – black dash line) and the cumulative proportion of
the Spike Y839 variant sequences (red line) detected in Portu-
gal during the same period.
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at a rate of 12.1% (6.1%–18.2%,CI 95%) every three days
between 14March and 9April, increasing from 13.3% to
33.1% (Figure 4). It was potentially associated with 3793
(3177–4542, CI 95%) COVID-19 cases in Portugal
during that period, representing 24.8% (20.8–29.7%,
CI 95%) of the total confirmed cases reported in the
same period (Figure 4). Hence, our data supports that
the Spike Y839 variant was circulating in Portugal
since mid-late February (more than one week before
the first COVID-19 confirmed case at 2 March 2020),
being most likely responsible for the largest SARS-
CoV-2 transmission chain occurred during the first 1–
1.5 months of COVID-19 epidemic in Portugal. In
particular, the Spike Y839 variant is strongly linked to
a large andworrying COVID-19 “local” outbreak occur-
ring in a small municipality (Ovar) in the coastal side of
the Central region of the country (District of Aveiro),
with 80% of the genomes collected from this municipal-
ity carrying the Y839 variant. Ovar was the onlymunici-
pality in Portugal mainland that was subjected to strict
local quarantine and lockdown measures (from 17
March to 17 April), presenting an incidence of 636
cases per 100 000 inhabitants in the last 14 days by 5
April. The Public Health Unit of Primary Care Cluster
of BaixoVouga (covering severalmunicipalities, includ-
ing Ovar), has been carrying out a deep investigation
Figure 2. Landscape of the geotemporal spread of SARS-CoV-2 Spike Y839 variant in Portugal by region, as of 30 April 2020. (A)
Distribution of the analysed genome sequences (n = 1500) by date of sample collection and Health Administration region, high-
lighting COVID-19 cases caused by the Spike Y839 variant (red dots). In y-axis, it is indicated, for each region, the number of
sequences analysed (n), the percentage of confirmed cases with SARS-CoV-2 genome data (% cases), the percentage of sequences
from each region in the whole dataset (% genomes) and the percentage of Y839 variant sequences (%Y839, in red), as of 30 April,
2020. (B) Radial maximum likelihood phylogenetic tree showing the high proportion of genomes with the Spike D839Y mutation
detected in Portugal [about 20% of all sequences collected until the end of March (255/1275) or the end of April (287/1500)]. This
dataset covers 15.5% (1275/8251) and 6.0% (1500/24987) of all confirmed cases detected until the end of March and April,
respectively. The phylogeny and geotemporal distribution can be visualized interactively at https://microreact.org/project/
nDGsJKFv7gQTj1q8CQwwKR/0489f840 (geographic resolution by Region) and https://microreact.org/project/
2kh3TRVYB9gWGRpNSJWDW5/b6c659e0 (geographic resolution by District) using Microreact (https://microreact.org/). (C) Distri-
bution of the Spike Y839 variant by Health Administration region, highlighting its high relative frequency in the Northern and
Central regions of Portugal, where this variant represented 22% and 59% of the sampled genomes until the end of April
2020, respectively. The size of the pie charts is proportional to the number of sequenced genomes. (D) Cumulative total number
of COVID-19 confirmed cases by Health Administration region, showing the Northern region as the “epicenter” of the epidemic
during the two first months (source: General Directorate of Health (DGS), https://covid19.min-saude.pt/relatorio-de-situacao/).
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leading to the identification of clusters of potential epi-
demiologically linked confirmed cases (“epiclusters”)
among 1556 monitored COVID-19 cases (by 30
April). Our SARS-CoV-2 genome collection (as of 30
April) includes samples representative of 41 of those
potential epiclusters (covering a total of 420 confirmed
cases), ofwhich 33 (323 confirmed cases, 77%) are exclu-
sively associatedwith the SpikeY839 variant (Figure S2).
In a conservative manner, it is reasonable to extrapolate
that the Spike Y839 variant is potentially associated with
about 1200 cases (77%of the total 1556monitored cases)
in the region covered by Primary Care Cluster of Baixo
Vouga. Still, the Spike Y839 variant disseminated far
beyond the coastal municipality ofOvar and neighbour-
hoodmunicipalities. In the inland region of the country,
Y839 variant was for instance linked to a large cluster of
infected individuals living/working in a nursing home in
Vila Nova de Foz Côamunicipality (District of Guarda)
detected by the end of March, and more than 50% of
Y839 genomes detected in April were collected in the
District of Viseu (Figure S1 and S3; https://microreact.
org/project/2kh3TRVYB9gWGRpNSJWDW5/
b6c659e0), which borders the district of Aveiro. In total,
the highly prevalent Spike Y839 variant was already
detected in 44municipalities across 11 out of the 18Dis-
tricts of Portugal mainland, consolidating that this des-
cendent variant of the globally spreadG614 varianthad a
remarkable weight in the early COVID-19 epidemic in
Portugal.
Detection and circulation of SARS-CoV-2 Spike
839 amino acid variants worldwide
To explore the frequency of SARS-CoV-2 D839Y
mutation (and other mutations in 839 protein pos-
ition) at worldwide level, we downloaded 66548
amino acid sequences (and associated metadata) of
SARS-CoV-2 Spike protein available at GISAID (as
of 23 July 2020). From the 65367 sequences collected
outside Portugal having data for the 839 position, 97
were found to display mutations in this amino acid
of interest (Table 1, Table S2). Of those, 92 genomes
revealed the same G24077T nucleotide substitution
(leading to the D839Y amino acid replacement) in a
SARS-CoV-2 with Spike G614 background. As pre-
viously noticed13, this data sustains that the global fre-
quency of amino acid variants in this 839 site remains
around 0.5% (similar estimates can be found in
https://cov.lanl.gov/content/index and https://bigd.
big.ac.cn/ncov/). After the first Spike Y839 variant
was detected in Italy (Lombardy) on 21 February,
the mutation D839Y has been reported in 12 other
countries from four continents (Europe, Oceania,
Asia and America) (Figure 5). Despite the highly
unequal sequencing “sampling” (i.e. proportion of
confirmed cases with SARS-CoV-2 genome data)
between the different countries, it is noteworthy that,
apart from Portugal, D839Y genomes represent ∼5%
of all sequences made available at GISAID (as of 23
July 2020) by three countries (Estonia, Georgia and
New Zealand) (Figure 5). Of note, the four genomes
detected in Iceland on early March are also associated
with travel history to Italy [15,27] (Table S2). Notwith-
standing, fine-tune integration of the 92 Spike Y839
genomes detected abroad in the “global” phylogeny
(using Nextstrain https://nextstrain.org/ncov and
Nextclade https://clades.nextstrain.org/) pointed out
that the D839Y amino acid change likely emerged
independently in two other instances. This obser-
vation is supported by one genome sequence collected
in the United Kingdom (Wales) on 24 April (Wales/
PHWC-35B01/2020; GISAID accession
EPI_ISL_474528), which presents all clade-defining
SNPs of Nextstrain Clade 20C plus four additional
SNPs (including G24077 T). In this particular case,
we cannot exclude the hypothesis that the G24077 T
nucleotide change might have been introduced in a
clade “20C” SARS-CoV-2 by recombination, as
“20C” and “20A harbouring Y839” viruses co-circu-
lated in Wales during the collection period (13 out
of the 51 Spike 839Y genomes from UK were collected
in Wales between 10 April and 25 May). The potential
third independent emergence of a Spike Y839 variant
is supported by the four genomes collected in India, as
they cluster apart from other G614+Y839 genomes,
forming a sub-branch (supported by 6 SNPs, includ-
ing G24077T) within a large cluster mostly enrolling
genomes from India.
Impact of Spike Y839 variant on viral load
The Cycle threshold (Ct) obtained in diagnostic PCR
is an indirect indicator for relative viral loads in
vivo, with lower Ct values indicating higher viral
loads. Increasing reports have been linking the glob-
ally dispersed Spike G614 variant to lower Ct values
[13,28,29], suggestive of higher upper respiratory
tract viral loads leading to increased G614 transmissi-
bility, but not pathogenicity [13]. INSA gathered Ct
values of 940 out of the 1516 genomes analyzed in pre-
sent study. Despite the expected bias associated with
sample collection (e.g. momentum), sampling (e.g.
selection) and testing (e.g. extraction, PCR protocol
and equipment) within datasets enrolling multiple lab-
oratories, we sought to verify whether the same trend
is observed for the D614/G614 comparison and
whether the Spike Y839 variant (Spike background
G614+Y839) may also be potentially linked with
changes in Ct values. As previously seen [13,28,29],
we observed that samples with Spike G614 had Ct
values (mean = 22.2; n = 844) lower than those with
D614 viruses (mean = 22.9; n = 96), although without
statistical significance (Figure S4). Considering the
phylogeny of SARS-CoV-2 in Portugal, we then
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compared Ct values according to D614/G614 status,
phylogenetic group within G614 (i.e. 20B or non-
20B) and D839/Y839 status (Figure S4; https://
microreact.org/project/nDGsJKFv7gQTj1q8CQwwKR/
f46f1fa4). Curiously, 20B clade (defined by the GGA-
to-AAC SNP triplet at genome position 28881-3)
revealed the lowest Ct values (mean = 21.7; n = 413)
among all groups, although without statistical signifi-
cance in pairwise comparisons. Regarding the D839/
Y839 comparison, we observed that Y839 presented
non-significant higher Ct values (mean = 22.7;
n = 220) than the ancestral D839 (mean = 22.1; n =
720). However, considering that D839 includes both
20B and non-20B samples, contrarily to Y839, which
is a sub-group within 20A (Figure S4), we repeated
the analysis by excluding 20B samples from the com-
parison and observed similar average Ct values in
D839 (mean = 22.6; n = 624) and Y839 (mean = 22.7;
n = 220) groups. When applying the same rationale
(i.e. excluding 20B) to the D614/G614 comparison,
the 0.7 difference observed in the mean Ct values
using the whole dataset decreased to less than 0.3.
Figure 3. Overview of the SARS-CoV-2 genome sequencing sampling and cumulative relative frequency of the circulating Spike
Y839 variant, as of 30 April 2020 (n = 1500), in the Northern (A) and Central (B) regions of Portugal. Area plots (left y-axis) reflect
the cumulative total number of COVID-19 confirmed cases (light blue) and SARS-CoV-2 genome sequences (dark blue) detected/
generated in each Health Administration region. Lines (right y-axis) display the cumulative percentage of COVID-19 confirmed
cases with SARS-CoV-2 genome data, i.e. sequencing sampling (blue dash line) and the cumulative proportion of the Spike
Y839 variant sequences (red line) detected in those regions during the same period.
Table 1. Overview of the SARS-CoV-2 Spike amino acid
sequences with mutations in the 839 site available at





















D839E G614 1 Netherlands (1) 28/Feb
D839N G614 1 Australia (1) 20/Jun
D839N D614 1 United Kingdom (1) 25/Mar
D839G D614 2 United Kingdom (2) 24/Mar–8/
May
aCountries are ordered by the date of collection of the first reported gen-
ome with the Spike 839 site variant. Individual sequences are detailed in
Table S1 (Portugal) and S2 (abroad).
bThe reported case in Estonia has March 2020 as the date of collection (31
March 2020 was assumed in the Figure 5). Two genomes (one from Uni-
ted Kingdom and another from India) only had the year of sampling
available. These were not included in Figure 5.
Figure 4. Increasing trajectory of the Spike Y839 variant and
estimated weight of this variant in the total number of
COVID-19 confirmed cases in early epidemic. A binomial
regression model with logarithmic link function was applied
to assess the temporal variation in the proportion of the
Y839 variant among sequenced samples (graph in the upper
left corner, showing an estimate increase from 13.3% to
33.1%). This model was then applied to extrapolate the evol-
ution of Y839 cases (red line) in the total confirmed case popu-
lation (gray bars) at each 3-day interval (main graph). Crosses
represent the estimated Y839 cases and the shaded region
shows the 95% confidence interval. 1-day was assumed as
the timeframe delay between sample collection and case
notification.
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Discussion
One of the main objectives of conducting genome-
based surveillance of circulating pathogens is to ident-
ify mutations potentially leading to fitness advantages
and/or immunological/drug resistance. In this per-
spective, mutations in the SARS-CoV-2 Spike D839
site, which is predicted to fall within the Spike fusion
peptide or proximal regions [2,13], are of particular
interest given both its non-negligible relative fre-
quency worldwide and the pivotal role of this protein
region in inserting SARS-CoV-2 into human cell
membranes [2,13]. In the present study, we show
that a SARS-CoV-2 variant with a Spike D839Y
mutation was associated with ∼25% of all COVID-
19 cases in Portugal during the exponential phase of
the epidemic, after its importation from Italy in
mid-late February 2020. Our data shows that it was
circulating in Portugal before the first COVID-19
confirmed case was detected on 2 March, becoming
notably prevalent in the Northern (22%) and Central
(59%) regions of the country by the end of April
2020 (Figures 2 and 3).
The massive dissemination of the Spike Y839 var-
iant in Portugal might be due to a populational/epide-
miological effect (founder effect). This variant was
likely one of the first SARS-CoV-2 to be introduced
in Portugal, so it might have had more opportunity
to spread. Its introduction is strongly linked to an
international trade fair in Milan with many Portu-
guese attendees. So, we can raise the possibility of sev-
eral “simultaneous” introductions of Y839 variant in
Portugal, although this scenario would likely imply
its circulation in the South of Portugal and abroad,
namely in Spain (also highly represented in the
event) where it has not been detected so far (http://
seqcovid.csic.es/nextspain/, as of 30 August) despite
the high sequencing sampling. The alternative scen-
ario of a single introduction is then plausible consider-
ing that travel history and contact tracing data
collected to date links all initial cases to a single indus-
trial area in the North of Portugal and does not indi-
cate additional introductions. Regardless of the
scenario, the increasing frequency trajectory of Spike
Y839 variant would not have been mitigated because
this variant disseminated well before the first
confirmed cases in Portugal, when contact tracing,
broad testing, and strict lockdown measures were
still not in place. For instance, on 9 March, case
definition for a COVID-19 suspected case did not
include individuals with acute respiratory infection,
unless they required hospitalization, reported travel
history or any contact with suspected or confirmed




perspective, one cannot rule out that the high dissemi-
nation could have also been driven by fitness increase
mediated by the D839Y mutation, which would be
consistent with its estimated frequency increase from
13.3% to 33.1% in a 4-week period. In this hypothesis,
this mutation would have posed “advantageous” struc-
tural changes in the Spike protein with potential
impact on SARS-CoV-2 infectivity and, consequently,
on its transmissibility, as suggested for D614G [13].
While D614G was hypothesized to increase SARS-
CoV-2 infectivity by influencing the dynamics of the
Figure 5. Detection and circulation of the SARS-CoV-2 Spike D839Y mutation worldwide. SARS-CoV-2 Spike amino acid sequences
available at GISAID (https://www.gisaid.org/), as of 23 July 2020, were download, aligned and screened for the presence of
mutations in Spike 839 amino acid position. The main plot displays the country and data of collection of 92 Spike sequences
with the D839Y mutation (detailed in Table S2). The bar graph in the upper right corner displays the proportion of D839Y
sequences in the total number of Spike amino acid sequences available per country. As detailed in Table S2, the D839Y sequence
from Estonia indicates March 2020 as the date of collection (31 March 2020 was assumed in this plot). Two genomes (one from
United Kingdom and another from India) only had the year of sampling available, thus they were not included in the graph.
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spatially proximal fusion peptide [13], D839Y, which
itself falls within functional fusogenic element of
Spike[2,13], could also have shaped this motif towards
a better fitted fusion of SARS-CoV-2 with human cells.
Also, recent data based on computational modeling
suggested that mutations in Spike D839 may
strengthen the interaction between the virus and
human T cells potentially influencing host inflamma-
tory responses [in particular, when replacing the
aspartic acid (D) to an aromatic tyrosine (Y)] [19],
and may influence Spike cleavage by host proteases
during SARS-CoV-2 fusion activation and entry
[20]. Nevertheless, these clues about the potential
impact of this mutation on SARS-CoV-2 transmissi-
bility/pathogenicity require evidence through exper-
imental validation to verify or rule out the fitness
advantage hypothesis. Although we did not observe
any association between Y839 and Ct values (viral
load) in our dataset, this assessment needs to be
revisited as more data is acquired and be complemen-
ted with other assays. Notwithstanding, we indirectly
observed that samples from clade 20B had a lower
mean Ct value than non-20B groups in our dataset,
supporting that it is worth performing this compari-
son with additional datasets and that the evaluation
of (sub)clade effects should not be neglected in this
kind of screenings.
Besides the potential functional role of D839Y
mutation and its high prevalence in Portugal, its detec-
tion in 12 other countries from four continents, it’s
probable independent emergence in distinct times
and genetic clades (20A and 20C) in some of these
countries and its considerable relative weight (∼5%)
in the sampled genomes of three countries (besides
Portugal) also indicate that the hypothesis of selective
advantage is not implausible. Contrarily to Spike G614
variant, which emerged way before the general quar-
antine in Europe, the Spike Y839 variant likely
emerged on mid-late February in Lombardy, Italy.
This is strongly corroborated by the detection of
both D839 and Y839 subpopulations in different ana-
tomical sites of the Y839-infected individual in Lom-
bardy, Italy, by 21 February [26]. At this time, rigid
lockdown measures started being implemented every-
where in Europe, which posed strong bottlenecks on
SARS-CoV-2 population, likely giving Y839 variant
less opportunity to expand, even if it was selectively
advantageous over other circulating variants. None-
theless, in Portugal, contrarily to what might have
happened in other countries, the timeline of the epi-
demics certainly favoured a high weight of “founder
effect” in the remarkable dissemination of the Y839
variant. For instance, first lockdowns in Lombardy,
Italy, where Spike Y839 variant was firstly detected
on 21 February, coincidently began on this date [30].
In contrast, in Portugal, first cases were confirmed in
2 March and national quarantine was implemented
on 18 March, when Spike Y839 variant had already
been circulating in the community for at least three
weeks. It is still worth highlighting that the huge dis-
crepancies in sequencing sampling between countries
completely hampers a real knowledge of D839Y fre-
quency regionally and globally. Our sequencing
sampling after 30 April does not allow us to infer
the current relative frequency of the Spike Y839 var-
iant in Portugal. One can speculate that its circulation
was highly contained considering that, after this
period, the epidemic evolved favourably in Northern
and Central regions (where Y839 had mostly circu-
lated), contrarily to the Lisbon and Tagus Valley
region (where Y839 was, at that time, rarely seen)
(http://www.insa.min-saude.pt/wp-content/uploads/
2020/08/Report_covid19_07_08_2020.pdf).
In summary, we describe the emergence and
increase in frequency of a Spike Y839 variant that
reached a tremendous impact on COVID-19 epidemic
in Portugal, as estimated by its high relative weight of
one in each four cases during the exponential phase of
the epidemic. Similarly to other major Spike variants,
Y839 certainly constitutes an important target for
functional and immunological studies. Our study
reinforces the need for continuous and close surveil-
lance of SARS-CoV-2 genetic diversity, with emphasis
on detecting and monitoring variants with potential
impact at biological and/or epidemiological levels.
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